Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $1.7 million for Q4 2025.

• Quarterly Current Deferred Revenue fell 15.0% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 15.0% YoY) and the FY2025 annual result came in at $1.7 million, down 15.0% from the prior year.
• Current Deferred Revenue was $1.7 million for Q4 2025 at Apyx Medical, down from $2.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.3 million in Q4 2022 and bottomed at $1.7 million in Q4 2023.
• A 5-year average of $1.9 million and a median of $1.9 million in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue soared 216.67% — and 2023, when it decreased 26.09%.
• Apyx Medical's Current Deferred Revenue stood at $1.9 million in 2021, then rose by 21.05% to $2.3 million in 2022, then fell by 26.09% to $1.7 million in 2023, then gained by 17.65% to $2.0 million in 2024, then decreased by 15.0% to $1.7 million in 2025.
• Business Quant data shows APYX's Current Deferred Revenue at $1.7 million in Q4 2025, $2.0 million in Q4 2024, and $1.7 million in Q4 2023.